Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.

Luessi F, Engel S, Spreer A, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 13;5(5):e481. doi: 10.1212/NXI.0000000000000481. eCollection 2018 Sep.

2.

Regulation of IL-22BP in psoriasis.

Voglis S, Moos S, Kloos L, Wanke F, Zayoud M, Pelczar P, Giannou AD, Pezer S, Albers M, Luessi F, Huber S, Schäkel K, Kurschus FC.

Sci Rep. 2018 Mar 23;8(1):5085. doi: 10.1038/s41598-018-23510-3.

3.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
4.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

5.

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.

Kroth J, Ciolac D, Fleischer V, Koirala N, Krämer J, Muthuraman M, Luessi F, Bittner S, Gonzalez-Escamilla G, Zipp F, Meuth SG, Groppa S.

Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474. [Epub ahead of print]

PMID:
29226779
6.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
7.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

8.

Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.

Schlöder J, Berges C, Luessi F, Jonuleit H.

Int J Mol Sci. 2017 Jan 28;18(2). pii: E271. doi: 10.3390/ijms18020271.

9.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.

10.

Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.

Ulges A, Witsch EJ, Pramanik G, Klein M, Birkner K, Bühler U, Wasser B, Luessi F, Stergiou N, Dietzen S, Brühl TJ, Bohn T, Bündgen G, Kunz H, Waisman A, Schild H, Schmitt E, Zipp F, Bopp T.

Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10145-50. doi: 10.1073/pnas.1523869113. Epub 2016 Aug 23.

11.

Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.

Bühler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C, Gollan R, Wolf C, Lutz J, Bar-Or A, Siffrin V, Zipp F.

Mult Scler. 2017 Apr;23(4):567-576. doi: 10.1177/1352458516658559. Epub 2016 Jul 21.

PMID:
27436357
12.

Increase of Alternatively Activated Antigen Presenting Cells in Active Experimental Autoimmune Encephalomyelitis.

Wasser B, Pramanik G, Hess M, Klein M, Luessi F, Dornmair K, Bopp T, Zipp F, Witsch E.

J Neuroimmune Pharmacol. 2016 Dec;11(4):721-732. Epub 2016 Jul 16.

PMID:
27423192
13.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

14.

The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion.

Hucke S, Herold M, Liebmann M, Freise N, Lindner M, Fleck AK, Zenker S, Thiebes S, Fernandez-Orth J, Buck D, Luessi F, Meuth SG, Zipp F, Hemmer B, Engel DR, Roth J, Kuhlmann T, Wiendl H, Klotz L.

Acta Neuropathol. 2016 Sep;132(3):413-31. doi: 10.1007/s00401-016-1593-6. Epub 2016 Jul 6.

PMID:
27383204
15.

Erratum to: Dendritic cells as therapeutic targets in neuroinflammation.

Luessi F, Zipp F, Witsch E.

Cell Mol Life Sci. 2016 Jul;73(13):2451. No abstract available.

PMID:
27105624
16.

Dendritic cells as therapeutic targets in neuroinflammation.

Luessi F, Zipp F, Witsch E.

Cell Mol Life Sci. 2016 Jul;73(13):2425-50. doi: 10.1007/s00018-016-2170-9. Epub 2016 Mar 12. Review. Erratum in: Cell Mol Life Sci. 2016 Jul;73(13):2451.

PMID:
26970979
17.

Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS.

Muthuraman M, Fleischer V, Kolber P, Luessi F, Zipp F, Groppa S.

Front Neurosci. 2016 Feb 2;10:14. doi: 10.3389/fnins.2016.00014. eCollection 2016.

18.

Genome-wide significant association with seven novel multiple sclerosis risk loci.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, Fernández O, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L.

J Med Genet. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16.

PMID:
26475045
19.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
20.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
21.

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.

Trinschek B, Luessi F, Gross CC, Wiendl H, Jonuleit H.

Int J Mol Sci. 2015 Jul 17;16(7):16330-46. doi: 10.3390/ijms160716330.

22.

Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.

Nemecek A, Zimmermann H, Rübenthaler J, Fleischer V, Paterka M, Luessi F, Müller-Forell W, Zipp F, Siffrin V.

Mult Scler. 2016 Apr;22(4):483-93. doi: 10.1177/1352458515593821. Epub 2015 Jul 10.

PMID:
26163073
23.

Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis.

Kolber P, Montag S, Fleischer V, Luessi F, Wilting J, Gawehn J, Gröger A, Zipp F.

J Neurol. 2015 Jun;262(6):1473-82. doi: 10.1007/s00415-015-7724-5. Epub 2015 Apr 11.

PMID:
25862481
24.

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, Bopp T, Jonuleit H, Jolivel V, Zipp F, Witsch E.

Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2.

PMID:
25732840
25.

Remyelinating strategies in multiple sclerosis.

Luessi F, Kuhlmann T, Zipp F.

Expert Rev Neurother. 2014 Nov;14(11):1315-34. doi: 10.1586/14737175.2014.969241. Review.

PMID:
25331418
26.

Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.

Fleischer V, Salmen A, Kollar S, Weyer V, Siffrin V, Chan A, Zipp F, Luessi F.

J Clin Neurol. 2014 Oct;10(4):289-95. doi: 10.3988/jcn.2014.10.4.289. Epub 2014 Oct 6.

27.

Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.

Leuenberger T, Pfueller CF, Luessi F, Bendix I, Paterka M, Prozorovski T, Treue D, Luenstedt S, Herz J, Siffrin V, Infante-Duarte C, Zipp F, Waiczies S.

PLoS One. 2014 Jul 11;9(7):e100871. doi: 10.1371/journal.pone.0100871. eCollection 2014.

28.

Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L.

Neurogenetics. 2014 May;15(2):129-34. doi: 10.1007/s10048-014-0396-y. Epub 2014 Mar 18.

PMID:
24638856
29.

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.

Kraus SH, Luessi F, Trinschek B, Lerch S, Hubo M, Poisa-Beiro L, Paterka M, Jonuleit H, Zipp F, Jolivel V.

Int Immunopharmacol. 2014 Feb;18(2):347-57. doi: 10.1016/j.intimp.2013.11.027. Epub 2013 Dec 5.

PMID:
24316255
30.

Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis.

Trinschek B, Luessi F, Haas J, Wildemann B, Zipp F, Wiendl H, Becker C, Jonuleit H.

PLoS One. 2013 Oct 14;8(10):e77634. doi: 10.1371/journal.pone.0077634. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi: 10.1371/annotation/0e76c09e-75b2-493a-90fd-cda3187a0888. Lüssi, Felix [corrected to Luessi, Felix].

31.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

32.

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium, Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Blaschke P, Buttmann M, Chan A, Compston A, Cournu-Rebeix I, Dörner T, Epplen JT, Fernández Ó, Gerdes LA, Guillot-Noël L, Hartung HP, Hoffjan S, Izquierdo G, Kemppinen A, Kroner A, Kubisch C, Kümpfel T, Li SC, Lindenberger U, Lohse P, Lubetzki C, Luessi F, Malhotra S, Mescheriakova J, Montalban X, Papeix C, Paredes LF, Rieckmann P, Steinhagen-Thiessen E, Winkelmann A, Zettl UK, Hintzen R, Vandenbroeck K, Stewart G, Fontaine B, Comabella M, Urcelay E, Matesanz F, Sawcer S, Bertram L, Zipp F.

Brain. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101.

33.

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

Jolivel V, Luessi F, Masri J, Kraus SH, Hubo M, Poisa-Beiro L, Klebow S, Paterka M, Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F, Waisman A.

Brain. 2013 Apr;136(Pt 4):1048-66. doi: 10.1093/brain/awt023. Epub 2013 Mar 20.

PMID:
23518712
34.

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, Corcia P, Otaegui D, Antigüedad A, Alcina A, Comabella M, Montalban X, Olascoaga J, Matesanz F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Rieckmann P, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Fontaine B, Zipp F, Vandenbroeck K, Bertram L.

J Med Genet. 2013 Mar;50(3):140-3. doi: 10.1136/jmedgenet-2012-101411. Epub 2013 Jan 12. No abstract available.

PMID:
23315543
35.

Neurodegeneration in multiple sclerosis: novel treatment strategies.

Luessi F, Siffrin V, Zipp F.

Expert Rev Neurother. 2012 Sep;12(9):1061-76; quiz 1077. doi: 10.1586/ern.12.59. Review.

PMID:
23039386
36.

Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.

Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, Izquierdo G, Antigüedad A, Hoffjan S, Cournu-Rebeix I, Gromöller S, Faber H, Liebsch M, Meissner E, Chanvillard C, Touze E, Pico F, Corcia P; ANZgene Consortium,{dagger}, Dörner T, Steinhagen-Thiessen E, Baeckman L, Heekeren HR, Li SC, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Fontaine B, Vandenbroeck K, Matesanz F, Urcelay E, Bertram L, Zipp F.

J Med Genet. 2012 Sep;49(9):558-62. doi: 10.1136/jmedgenet-2012-101175. Erratum in: J Med Genet. 2012 Oct;49(10):668.

PMID:
22972946
37.

Influence of visual cues on gait in Parkinson's disease during treadmill walking at multiple velocities.

Luessi F, Mueller LK, Breimhorst M, Vogt T.

J Neurol Sci. 2012 Mar 15;314(1-2):78-82. doi: 10.1016/j.jns.2011.10.027. Epub 2011 Nov 17.

PMID:
22099639
38.

Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample.

Lill CM, Schjeide BM, Akkad DA, Blaschke P, Winkelmann A, Gerdes LA, Hoffjan S, Luessi F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Bertram L, Zipp F.

Neurogenetics. 2012 Feb;13(1):83-6. doi: 10.1007/s10048-011-0305-6. Epub 2011 Nov 18.

PMID:
22095036
39.

Neurocysticercosis with a single brain lesion in Germany: a case report.

Luessi F, Sollors J, Frauenknecht K, Schwandt E, Mueller HD, Stoeter P, Blum J, Thoemke F.

Cases J. 2009 Sep 9;2:8692. doi: 10.1186/1757-1626-0002-0000008692.

40.

Infliximab in the treatment of rheumatoid meningoencephalitis.

Luessi F, Sollors J, Müller H, Stoeter P, Sommer C, Vogt T, Birklein F, Thömke F.

J Neurol. 2009 Dec;256(12):2094-6. doi: 10.1007/s00415-009-5286-0. No abstract available.

PMID:
19707811
41.

Eosinophilic meningitis due to Angiostrongylus cantonensis in Germany.

Luessi F, Sollors J, Torzewski M, Müller HD, Siegel E, Blum J, Sommer C, Vogt T, Thömke F.

J Travel Med. 2009 Jul-Aug;16(4):292-4. doi: 10.1111/j.1708-8305.2009.00337.x.

42.

Re: Hypergonadotropic hypogonadism in a patient with inv ins (2;4).

Luessi F, Sollors J, Knabe J, Vogt T.

Int J Androl. 2009 Aug;32(4):429. doi: 10.1111/j.1365-2605.2008.00934.x. Epub 2008 Dec 9. No abstract available.

PMID:
19076255
43.

Clinical studies with transdermal rotigotine in early Parkinson's disease.

Poewe W, Luessi F.

Neurology. 2005 Jul 26;65(2 Suppl 1):S11-4. Review. No abstract available. Erratum in: Neurology. 2005 Oct 25;65(8):1328.

PMID:
16030290
44.

Aspartate(69) of the calcitonin-like receptor is required for its functional expression together with receptor-activity-modifying proteins 1 and -2.

Ittner LM, Luessi F, Koller D, Born W, Fischer JA, Muff R.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1203-9.

PMID:
15194494

Supplemental Content

Loading ...
Support Center